Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

Cosnes, J.; Nion-Larmurier, I; Beaugerie, L.; Afchain, P.; Tiret, E.; Gendre, J-P
February 2005
Gut;Feb2005, Vol. 54 Issue 2, p237
Academic Journal
Background/Aim: Immunosuppressants are now used much earlier in the course of Crohn's disease; however their effect on the natural history of the disease, especially on the need for surgery, is not known. The aim of this study was to assess the evolution of the need for surgery in Crohn's disease during the last 25 years. Patients and Methods: The medical charts ci 2573 patients were reviewed retrospectively. The use of immunosuppressants (azathioprine or methotrexate), the need For intestinal resection, and the occurrence of intestinal complications were assessed using Kaplan-Meier analysis in five consecutive cohorts of patients defined by the date of diagnosis of Crohn's disease (1978-82; 1983-87; 1988-92; 1993-97; 1998-2002). Results: In 565 patients seen in the authors' unit within the first three months after diagnosis, characteristics of Crohn's disease at diagnosis did not differ from one cohort to another. The five year cumulative probability to receive immunosuppressants increased from 0 in the 1978-82 cohort to 0.13, 0.25, 0.25, and 0.56 in the 1983-87, 1988-92, 1993-97, and 1998-2002 cohorts, respectively (p<0.001). Concomitantly, the cumulative risk of intestinal resection remained unchanged (from 0.35 to 0.34 at five years; p =0.81). The cumulative risk of developing a stricturing or a penetrating intestinal complication remained also unchanged. Similar results were obtained in the 2008 patients seen during the same period who were referred to us more than three months after diagnosis. Conclusion: Although immunosuppressants have been used more frequently over the last 25 years, there was no significant decrease of the need for surgery, or of intestinal complications of Crohn's disease.


Related Articles

  • Immunomodulation does not alter histology in resected Crohn’s disease. Frizelle, F. A.; Ing, A.; Gearry, R. B.; Whitehead, M.; Faragher, I. G.; Dobbs, B. // Techniques in Coloproctology;Dec2009, Vol. 13 Issue 4, p295 

    The use of immunomodulators (Azathioprine, 6-Mercaptopurine and Methotrexate) and biological agents (Infliximab and adalimumab) for the treatment of Crohn’s disease (CD) has increased in the recent years with the aim of treating the inflammatory component of the disease and hoping to...

  • Infliximab in Takayasu arteritis: a safe alternative? Karageorgaki, Zaharenia Th.; Mavragani, Clio P.; Papathanasiou, Matthilde A.; Skopouli, Fotini N. // Clinical Rheumatology;Jun2007, Vol. 26 Issue 6, p984 

    To test the efficacy of Infliximab, a chimeric monoclonal antibody against TNF-α, in the treatment of Takayasu arteritis. We used infliximab at an initial dose of 3 mg/kg i.v. at weeks 0, 2, 6, and 8 thereafter in combination with methotrexate or azathioprine, to treat four patients with...

  • Conservative Laparoscopic And Medical Treatment For Cornual Pregnancy. Inizi, Shamma Al; Cheema, Masroor; Bamigboye, Vincent // Internet Journal of Gynecology & Obstetrics;2008, Vol. 8 Issue 2, p9 

    Cornual pregnancy is the least common type of ectopic pregnancy, occurring in less than 3% of cases and less than 1/100,000 maternities [1][2] . Cornual resection along with salpingectomy has been the treatment of choice in patients with no concern for future fertility [3] . However,...

  • The Impact of Timing and Duration of Thiopurine Treatment on First Intestinal Resection in Crohn's Disease: National UK Population-Based Study 1989-2010. Chatu, Sukhdev; Saxena, Sonia; Subramanian, Venkataraman; Curcin, Vasa; Yadegarfar, Ghasem; Gunn, Laura; Majeed, Azeem; Pollok, Richard C G // American Journal of Gastroenterology;Mar2014, Vol. 109 Issue 3, p409 

    OBJECTIVES:The efficacy of thiopurines (TPs) in altering the risk of surgery in Crohn's disease (CD) remains controversial. We evaluated the impact of TP therapy, optimal timing, and duration of TP therapy on first intestinal resection rates using a population-based cohort.METHODS:We constructed...

  • A woman who couldn't speak: report of methotrexate neurotoxicity. Szawarski, P.; Chapman, C. S. // Postgraduate Medical Journal;Mar2005, Vol. 81 Issue 953, p194 

    The association between methotrexate therapy and idiosyncratic neurological complications is well recognised in children. This case illustrates the importance of considering the diagnosis of methotrexate toxicity in an adult patient with behavioural and speech disturbances, who received it by...

  • Adalimumab.  // Reactions Weekly;7/9/2011, Issue 1359, p6 

    The article describes two cases of women with Crohn's disease who developed mural aortic thrombosis while undergoing adalimumab therapy.

  • Adalimumab.  // Reactions Weekly;7/9/2011, Issue 1359, p6 

    The article describes the case of a 54-year-old woman with Crohn's disease who developed vitiligo while receiving treatment with adalimumab.

  • Antineoplastics/ immunosuppressants.  // Reactions Weekly;7/30/2011, Issue 1362, p7 

    The article describes several cases of patients who developed encephalopathy while undergoing antineoplastic or immunosuppressant therapy.

  • Antineoplastics/immunosuppressants.  // Reactions Weekly;6/23/2012, Issue 1407, p11 

    The article describes cases of five paediatric patients who developed encephalopathy during treatment with antineoplastics or immunosuppressants.


Read the Article


Sign out of this library

Other Topics